Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $301.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target upped by research analysts at Piper Sandler from $232.00 to $301.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s price objective indicates a potential upside of 25.73% from the company’s current price.

Several other equities research analysts have also recently issued reports on JAZZ. Truist Financial raised Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Wells Fargo & Company increased their target price on Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Barclays increased their target price on Jazz Pharmaceuticals from $225.00 to $234.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Robert W. Baird set a $252.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Sanford C. Bernstein assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday. They issued a “market perform” rating and a $229.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.53.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of Jazz Pharmaceuticals stock opened at $239.40 on Friday. The company has a market capitalization of $15.02 billion, a P/E ratio of -11,964.02, a P/E/G ratio of 0.43 and a beta of 0.27. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a fifty day moving average of $201.35 and a 200 day moving average of $179.57. Jazz Pharmaceuticals has a fifty-two week low of $105.00 and a fifty-two week high of $242.18.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion during the quarter. On average, sell-side analysts anticipate that Jazz Pharmaceuticals will post 20.75 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Norbert G. Riedel sold 3,415 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the transaction, the director owned 7,024 shares of the company’s stock, valued at $1,348,608. The trade was a 32.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Patricia Carr sold 1,287 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $182.94, for a total value of $235,443.78. Following the sale, the chief accounting officer owned 6,512 shares of the company’s stock, valued at approximately $1,191,305.28. This represents a 16.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 74,015 shares of company stock valued at $14,180,486 over the last quarter. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $36,000. LRI Investments LLC purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $38,000. Westpac Banking Corp purchased a new stake in Jazz Pharmaceuticals during the 1st quarter valued at about $51,000. Leonteq Securities AG purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at about $50,000. Finally, Root Financial Partners LLC grew its stake in Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after purchasing an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.